Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKN1 | Q16512 | 5/20 | 0.76 |
| ▸ | PAK4 | O96013 | 4/20 | 0.76 |
| ▸ | PAK1 | Q13153 | 5/20 | 0.69 |
| ▸ | PAK2 | Q13177 | 4/20 | 0.61 |
| ▸ | PAK3 | O75914 | 3/20 | 0.61 |
| ▸ | WEE1 | P30291 | 2/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.55 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.55 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.55 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.51 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.49 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13553470 | 0.93 | PAK1 (0.81) | PKN1PAK4PAK1PAK2PAK3 | |
| SCHEMBL13553602 | 0.93 | PAK1 (0.81) | PKN1PAK4PAK1PAK2PAK3 | |
| SCHEMBL13553533 | 0.92 | PKN1 (0.66) | PKN1PAK4PAK1PAK2PAK3 | |
| SCHEMBL13553476 | 0.91 | PKN1 (0.64) | PKN1PAK4PAK1PAK2PAK3 | |
| SCHEMBL14824675 | 0.89 | PKN1 (0.77) | PKN1PAK4PAK1PAK2PAK3 | |
| SCHEMBL13553474 | 0.89 | PAK1 (0.78) | PKN1PAK4PAK1PAK2PAK3 | |
| SCHEMBL13553532 | 0.89 | PKN1 (0.66) | PKN1PAK4PAK1PAK2PAK3 | |
| SCHEMBL15030436 | 0.88 | PKN1 (0.74) | PKN1PAK4PAK1PAK2PAK3 | |
| SCHEMBL14824759 | 0.88 | PKN1 (0.76) | PKN1PAK4PAK1PAK2PAK3 | |
| SCHEMBL15035189 | 0.88 | PKN1 (0.76) | PKN1PAK4PAK1PAK2PAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8372970-B2 | 8-ethyl-6-(aryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372970-B2 | 8-ethyl-6-(aryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-20120270866-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270866-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS INC. (US) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270866-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK5 | PKN1 528/4885PAK4 6/4885PAK1 5/4885 |
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK5 | PKN1 528/4885PAK4 6/4885PAK1 5/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | PKN1 326/4885PAK4 5/4885PAK1 4/4885 |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | PAK2, PAK1, PAK6 | PKN1 182/4885PAK4 5/4885PAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.